If you are launching a nutraceutical, health supplement, or functional food brand in India, FSSAI’s Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food Regulations — known in shorthand as Schedule IV — quietly governs everything from your ingredient list to your packaging artwork. Most first-time brand owners discover its requirements only after a regulatory officer flags a label, and by then there is product sitting in a warehouse that cannot ship. This primer is the version of Schedule IV that would have saved you that quarter — written for founders and brand operators, not for regulatory lawyers.
What Schedule IV actually covers
The regulation, formally notified in 2016 and updated several times since, governs eight product categories: health supplements, nutraceuticals, food for special dietary use, food for special medical purpose, specialty food containing plant or botanical ingredients, food containing probiotics, food containing prebiotics, and novel foods. If your product is intended to “supplement the normal diet” with vitamins, minerals, amino acids, enzymes, botanical extracts, or other bioactive substances — and it is sold in a measured dose form (capsule, tablet, sachet, syrup, liquid, powder) — Schedule IV applies.
What it does not cover: ordinary food products, traditional Indian foods (unless they make a health claim), and pharmaceutical drugs (which fall under CDSCO, not FSSAI). The boundary between a “functional food” and an “ordinary food with a health benefit” is often where first-time brands get confused — making a structural-function claim on a regular food product can push it into Schedule IV territory unintentionally.
The four pillars every brand owner has to get right
1. Ingredient list compliance
FSSAI maintains a positive list of permitted ingredients for nutraceuticals, with maximum daily doses specified for each. A formulation containing an ingredient not on the positive list — or above the permitted dose — cannot be legally sold as a nutraceutical without prior product approval, which adds 12–18 months to the launch timeline. Common trip-ups: novel botanical extracts, certain amino acids at higher-than-permitted doses, and any ingredient categorised as a “novel food” without prior approval. The fix is upstream: validate every ingredient against the current positive list before formulation freeze, not after.
2. Label claim substantiation
FSSAI permits two categories of claims — nutrient content claims (“high in protein,” “source of vitamin C”) and health claims (function claims like “supports immune health,” reduction-of-disease-risk claims like “may reduce risk of osteoporosis”). Every health claim requires scientific substantiation in the form of peer-reviewed evidence, and the claim language must match FSSAI-approved formats. “Boosts immunity” is not a permitted claim. “Vitamin C contributes to the normal function of the immune system” is, when supported by adequate vitamin C content per serving. The label-claim review is where most first-time brand artwork fails inspection.
3. Mandatory label disclosures
Every nutraceutical or health supplement label must carry: the words “HEALTH SUPPLEMENT” or “NUTRACEUTICAL” prominently displayed, the FSSAI license number, the green vegetarian or brown non-vegetarian symbol, the nutritional information panel in the FSSAI-prescribed format, the ingredient list in descending order by weight, the recommended daily dose, an advisory statement (commonly “not for medicinal use” or “to be consumed under medical supervision” depending on category), allergen declarations, batch number, manufacturing date, expiry date, and the manufacturer’s address. Missing any of these is a label-rejection waiting to happen.
4. Manufacturing and testing requirements
Schedule IV products must be manufactured in facilities licensed under the FSSAI nutraceutical category, with documented standard operating procedures, in-process quality controls, finished product testing per batch (assay, microbial limits, heavy metals, contaminants per the FSSAI-specified panels), and stability data supporting the claimed shelf life. Brand owners who outsource manufacturing to a contract partner inherit the partner’s licensing and quality systems — which is why partner selection has more long-term regulatory consequence than most brand owners initially appreciate.
Where new brands most often trip up
Four mistakes account for most regulatory issues we see new brands face.
The first is formulating before validating the positive list. A formulation is finalised, packaging artwork is designed, marketing campaign is planned — and then someone notices that the headline active ingredient sits above the FSSAI maximum daily dose. The fix is a six-month delay; the avoidance is a 30-minute regulatory check before formulation freeze.
The second is writing label copy as marketing rather than regulation. “Boosts energy,” “fat-burning formula,” “immunity booster” — none of these are permitted claims in FSSAI’s framework. Brand owners often fight to keep punchy claims that then fail the label review. The fix is to write the regulatory-compliant claim first, then build the marketing around it.
The third is under-investing in the Certificate of Analysis. Every batch shipped should carry a CoA documenting assay, micro panel, heavy metals, and contaminant testing. Brand owners who rely on the manufacturer’s stated CoA without independent third-party verification are accepting unverified risk — and when a batch fails a regulatory audit, the brand carries the consequence, not the manufacturer.
The fourth is missing the import licence trail for foreign ingredients. Many premium nutraceutical actives are imported. Each imported ingredient requires documentation of its FSSAI import compliance, supplier qualification, and country-of-origin disclosure on the label. Brand owners who source through traders without this paper trail discover the gap during their first regulatory inspection.
The decisions that compound
Two early choices have outsized regulatory consequences down the road. Contract manufacturer selection determines your inherited licensing, quality system, batch documentation, and traceability — all of which are audited together. Choosing a partner whose Schedule IV systems are mature pays back across every batch for the life of the brand. Product category positioning — is your product a health supplement, a nutraceutical, a functional food, or a food for special dietary use? — determines which Schedule IV chapter applies and which label format, dose limits, and claim language you can use. Getting this categorisation right at the formulation stage is far easier than re-positioning a launched product.
FSSAI Schedule IV compliance is not a hurdle to be cleared at the end of the launch process; it is a constraint that shapes good formulation, smart positioning, and credible labelling from the start. The brands that thrive in this category treat regulation as a design input, not a hurdle, and they pick manufacturing partners whose quality systems are built around it. At Horta Nutrition, we manufacture Schedule IV-compliant nutraceuticals, health supplements, and functional foods across our full product range with the licensing, batch documentation, and stability data that lets brand owners pass regulatory inspection cleanly. If you are mapping out a launch and want a manufacturing partner whose compliance work travels with the brand, submit a brief and our team will respond with a tailored proposal within 48 hours.
